Navigation Links
Novel Gene Therapy Agent NLX-P101 Effective in Treating Parkinson's Disease in Phase 2 Trial
Date:3/16/2011

FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) were published in an online-first edition of The Lancet Neurology. The randomized, double-blind, sham surgery-controlled trial of 45 subjects with advanced PD met its primary outcome measurement for efficacy and demonstrated that NLX-P101 gene therapy was safe and well-tolerated over the six month blinded study period.

Study results show that NLX-P101 treatment led to a mean 23.1 percent improvement (8.1 points) in off-medication Unified PD Rating Scale (UPDRS) motor score at the six-month study end-point, compared to a mean 12.7 percent (4.7 points) improvement with sham treatment. Improved motor control in the NLX-P101 group was seen at one month and continued virtually unchanged throughout the blinded study period.  The improvement in UPDRS motor scores from baseline in the NLX-P101 group was significantly greater than sham subjects over the six month study period (p=0.04).

Study results also show that 50% of subjects treated with NLX-P101 achieved previously defined moderate-to-large clinically-meaningful symptom improvements (> / = 9 points in UPDRS), compared to just 14% of subjects who received a sham surgical treatment (p=0.03). No serious adverse events (SAEs) related to the gene therapy or surgical procedure were reported.

"This is the first Phase 2 study conducted under a rigorous randomized, double-blind, sham-controlled surgical design to conclusively demonstrate that gene therapy can be effective for neurological diseases. This confirms our Phase I results and indicates that NLX-P101 may provide a safe, effective and minimally invasive treatment option for patients with PD
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" ... under the trade name of Avastin, bevacizumab injection is ... 2010, it was approved by CFDA to treat metastatic ... China all come from Roche and its ...
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Foundation, in collaboration with Kessler Institute for Rehabilitation, announced ... exoskeleton investigational studies, which will commence October 17.  Made ... exoskeleton that enables wheelchair users to stand and walk. ... both its company name and product line on October ...
... Ill., Oct. 14, 2011 Pregis Corporation, a ... packaging products and specialty packaging solutions, announced today ... agreement to sell its Kobusch-Sengewald business unit to ... European adviser to Sun Capital Partners, Inc., for ...
Cached Medicine Technology:Kessler Foundation Identifies Six Participants to Test Ekso 2Kessler Foundation Identifies Six Participants to Test Ekso 3Kessler Foundation Identifies Six Participants to Test Ekso 4Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 2Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 3
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
(Date:8/28/2015)... ... 28, 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili ... patients can currently receive a one hour treatment of this teeth whitening option. ... a number of unique features that can turn teeth up to nine shades whiter. ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe ... seeking to go deep sea diving. The act of recreational diving exposes ... for these reasons, it is vital that all recreational and professional divers undergo ...
(Date:8/28/2015)... , ... August 28, 2015 ... ... Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on two ... demonstration approved for a December 2015 launch; and Idaho’s partnership to revamp ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2
... ... , ... 17, 2010 -- SleepBetter.org, the web,s premier source for news, tips, and information on how ... to help their children settle down for a good night,s sleep. The Bedtime Stories ...
... ... milk chocolate-covered cereal snack for added flavor and crunch , ... Hicksville, NY (PRWEB) June 17, 2010 -- Whether it’s a ... JUST CEREAL , a new milk chocolate-coated cereal snack sold at Walmart in the candy ...
... costlier drugs increased after new rules took effect, study ... in Medicare payments to doctors who administer outpatient chemotherapy ... among Medicare recipients, finds a new study. , "This ... would expect, but economists often encounter this sort of ...
... ... made up of three products: Semantics.Datacenter, Semantics.Server, and Semantics.Framework. Semantics.Datacenter v 2.0 measures ... (Berlin 100M 5/25/10). , ... Brattleboro, VT (PRWEB) June 17, 2010 -- Intellidimension, Inc. a leading ...
... ... Implementation , ... Ontario (PRWEB) June 17, 2010 -- Phybridge Inc.,a leading provider of IP telephony ... from Avaya, a leading global provider of business communications applications, systems and services. ...
... ... to be “Stay-Cations” with a house boating trip at Sunset Marina and Resort. Beautiful ... by the beautiful hills of Tennessee. , ... Byrdstown, TN (PRWEB) June 17, 2010 -- Families are flocking ...
Cached Medicine News:Health News:Sleep Tips Web Site SleepBetter.org Expands The Bedtime Stories Project 2Health News:Sleep Tips Web Site SleepBetter.org Expands The Bedtime Stories Project 3Health News:Top Off Your Favorite Summer Treat with NOT JUST CEREAL™ 2Health News:Top Off Your Favorite Summer Treat with NOT JUST CEREAL™ 3Health News:Medicare Cuts May Have Led Docs to Prescribe More Chemo 2Health News:Intellidimension Releases New Version of Semantic Web Technologies 2Health News:Phybridge Network Solution Achieves Avaya “Compliant” Status 2Health News:Phybridge Network Solution Achieves Avaya “Compliant” Status 3Health News:Sunset Marina and Resort on Tennessee's Dale Hollow Lake Provides Affordable Houseboat Vacations for Price-Conscious Families 2
... Philadelphia™ Collar and Stabilizer Plastazote® ... reinforcements. Hook-and-pile closure straps. Chin ... mandibular pieces may be interchanged ... easily to the standard Philadelphia ...
Bougie Urethrotomes for slitting the female urethra and for meatus stenosis in males...
Optical Mini Urethrotome for telescope 3.3 mm, 0...
... flexible cystoscope is being used more and more ... its outstanding optical quality and large working/irrigation channel, ... and therapy. The outstanding flexibility of the cystoscope ... patient. Being ...
Medicine Products: